Topics

Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from USD $3500

05:19 EDT 15 Aug 2019 | BioPortfolio Report Blog

Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR Pipeline Review, H1 2019


Summary


According to the recently published report 'Leptin Receptor Pipeline Review, H1 2019'; Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR pipeline Target constitutes close to 7 molecules.


Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR Leptin receptor or LEPR is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetiteregulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamopituitaryadrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic betacell function and insulin secretion, is proangiogenic and affects innate and adaptive immunity.


The report 'Leptin Receptor Pipeline Review, H1 2019' outlays comprehensive information on the Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I and Preclinical stages are 1 and 6 respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Oncology and Ophthalmology which include indications Obesity, Lipodystrophy Lipoatrophy, Alzheimer's Disease, Breast Cancer, Choroidal Neovascularization, Type 1 Diabetes Juvenile Diabetes and Type 2 Diabetes.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR

The report reviews Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR targeted therapeutics and enlists all their major and minor projects

The report assesses Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Leptin Receptor HuB219 or OB Receptor or CD295 or LEPR Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from USD $3500"

Quick Search

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...